2 Dividend Stocks That Could Double Your Return in 10 Years
Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have produced strong total returns over the past decade, and both pharmaceutical companies have what it takes to keep up the pace going forward, despite looming patent cliffs for both.
Over the past five years, AbbVie's total return is 249%, and Pfizer's is 167%, and given their strong cash flow and ability to purchase assets and develop their own therapies with large pipelines, there are plenty of reasons to see the two dividend stocks doubling your return over the next decade.
Pfizer is off to a record year, with management saying in its third-quarter earnings report that it expects annual revenue between $99.5 billion to $102 billion, which at the midpoint represents a rise of 23.9% over 2021. Management also forecasts annual earnings per share (EPS) to be between $6.40 to $6.50, compared to $3.99 last year. The stock is down more than 9% for the year, which is why the company is trading at slightly more than 10 times earnings. It's a bargain now that should pay off for the next decade.
Source Fool.com
